Co-founder/Chief Scientific Officer
OZ-Link Technologies
ozlinktech.com
Website unreachable since Oct 24, 2026
OZ-Link Technologies has developed a modular platform utilizing self-cleaving chemical linkers for precise, time-controlled release of therapeutics, ranging from minutes to weeks. This technology enhances pharmacokinetics and minimizes off-target effects, making it suitable for a variety of applications, including small molecules, biologics, and vaccines.
- Biotechnology
Updated 7 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Problem
Current therapeutic delivery methods often lack precise control over drug release timing, leading to suboptimal pharmacokinetics and increased off-target effects. This lack of control can reduce drug efficacy and increase the risk of adverse reactions, particularly for sensitive molecules like biologics and vaccines.
Solution
OZ-Link Technologies offers a modular platform based on self-cleaving chemical linkers that enable precise, time-controlled release of therapeutics. These linkers can be customized to release drugs over a range of timescales, from minutes to weeks, allowing for optimized drug delivery profiles. By controlling the timing of drug release, OZ-Link's technology enhances pharmacokinetics, minimizes off-target effects, and improves the overall therapeutic index of various drug modalities, including small molecules, biologics, and vaccines.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions developing novel therapeutics or seeking to improve the delivery of existing drugs.
Features
- Customizable self-cleaving chemical linkers for controlled drug release
- Tunable release kinetics ranging from minutes to weeks
- Modular platform adaptable to various therapeutic modalities (small molecules, biologics, vaccines)
- Enhanced pharmacokinetics and reduced off-target effects